BACKGROUND: Whereas the presence of a lymphoid infiltrate has been associated with a favourable prognosis in colorectal carcinoma, the proliferative and cytotoxic responses of freshly isolated tumour infiltrating lymphocytes are frequently impaired. In mice, tumour induced immune suppression has been associated with a decreased expression of the zeta-chain of the T cell receptor (TCR)-CD3 complex, and loss of mRNA for granzyme B. AIM: To compare the expression of TCR-zeta and granzyme B in lymphocytes infiltrating normal colonic mucosa and Duke's A and D colorectal carcinomas. SPECIMENS: Paraffin wax embedded normal (n = 10) and malignant colonic mucosa (seven Dukes's A, nine Dukes's D). METHOD: Immunohistochemistry. RESULTS: The numbers of TCR-zeta + lymphocytes decreased from normal mucosa to Dukes's D carcinomas. In contrast, granzyme B+ lymphocytes were more frequent in Dukes's A carcinomas than in normal mucosa, but disappeared from advanced stage tumours. Granzyme B expressing cells were mainly CD3- (natural killer/lymphokine activated killer cells) in normal mucosa, but CD3+ in tumours, indicating the presence of activated cytotoxic T lymphocytes. In vitro culture of tumour infiltrating lymphocytes rapidly restored the expression of both molecules. CONCLUSION: The frequency of TCR-zeta + and granzyme B+ lymphocytes is decreased in advanced stage colorectal carcinomas. The restoration of expression during in vitro stimulation suggests the presence of tumour derived suppressive factors in situ.
BACKGROUND: Whereas the presence of a lymphoid infiltrate has been associated with a favourable prognosis in colorectal carcinoma, the proliferative and cytotoxic responses of freshly isolated tumour infiltrating lymphocytes are frequently impaired. In mice, tumour induced immune suppression has been associated with a decreased expression of the zeta-chain of the T cell receptor (TCR)-CD3 complex, and loss of mRNA for granzyme B. AIM: To compare the expression of TCR-zeta and granzyme B in lymphocytes infiltrating normal colonic mucosa and Duke's A and D colorectal carcinomas. SPECIMENS: Paraffin wax embedded normal (n = 10) and malignant colonic mucosa (seven Dukes's A, nine Dukes's D). METHOD: Immunohistochemistry. RESULTS: The numbers of TCR-zeta + lymphocytes decreased from normal mucosa to Dukes's D carcinomas. In contrast, granzyme B+ lymphocytes were more frequent in Dukes's A carcinomas than in normal mucosa, but disappeared from advanced stage tumours. Granzyme B expressing cells were mainly CD3- (natural killer/lymphokine activated killer cells) in normal mucosa, but CD3+ in tumours, indicating the presence of activated cytotoxic T lymphocytes. In vitro culture of tumour infiltrating lymphocytes rapidly restored the expression of both molecules. CONCLUSION: The frequency of TCR-zeta + and granzyme B+ lymphocytes is decreased in advanced stage colorectal carcinomas. The restoration of expression during in vitro stimulation suggests the presence of tumour derived suppressive factors in situ.
Authors: C M Loeffler; M J Smyth; D L Longo; W C Kopp; L K Harvey; H R Tribble; J E Tase; W J Urba; A S Leonard; H A Young Journal: J Immunol Date: 1992-08-01 Impact factor: 5.422
Authors: Y Horio; T Takahashi; T Kuroishi; K Hibi; M Suyama; T Niimi; K Shimokata; K Yamakawa; Y Nakamura; R Ueda Journal: Cancer Res Date: 1993-01-01 Impact factor: 12.701
Authors: J R Yannelli; D B Crumpacker; R W Good; C D Friddell; R Poston; S Horton; J R Maleckar; R K Oldham Journal: J Immunol Methods Date: 1990-06-12 Impact factor: 2.303
Authors: P J Peters; J Borst; V Oorschot; M Fukuda; O Krähenbühl; J Tschopp; J W Slot; H J Geuze Journal: J Exp Med Date: 1991-05-01 Impact factor: 14.307
Authors: Moritz Koch; Philipp Beckhove; Jan Op den Winkel; Daniel Autenrieth; Philipp Wagner; Daniel Nummer; Sebastian Specht; Dalibor Antolovic; Luis Galindo; Friedrich H Schmitz-Winnenthal; Volker Schirrmacher; Markus W Büchler; Jürgen Weitz Journal: Ann Surg Date: 2006-12 Impact factor: 12.969
Authors: Anna E Prizment; Robert A Vierkant; Thomas C Smyrk; Lori S Tillmans; Heather H Nelson; Charles F Lynch; Thomas Pengo; Stephen N Thibodeau; Timothy R Church; James R Cerhan; Kristin E Anderson; Paul J Limburg Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-12-15 Impact factor: 4.254
Authors: A M Deakin; K Singh; J S Crowe; J H Ellis; A Dalgleish; R J Leicester; C J Finlayson; W F Miles; P F Life Journal: Clin Exp Immunol Date: 1999-11 Impact factor: 4.330
Authors: Jan Friederichs; Robert Rosenberg; Joerg Mages; Klaus-Peter Janssen; Christian Maeckl; Hjalmar Nekarda; Bernhard Holzmann; Joerg-Ruediger Siewert Journal: Int J Colorectal Dis Date: 2005-05-10 Impact factor: 2.571
Authors: Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan Journal: J Transl Med Date: 2011-03-04 Impact factor: 5.531
Authors: Andrzej Eljaszewicz; Małgorzata Wiese; Anna Helmin-Basa; Michal Jankowski; Lidia Gackowska; Izabela Kubiszewska; Wojciech Kaszewski; Jacek Michalkiewicz; Wojciech Zegarski Journal: Mediators Inflamm Date: 2013-03-17 Impact factor: 4.711